LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $1.50 price objective on the stock.

A number of other research firms have also recently weighed in on LVTX. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. JMP Securities reiterated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.17.

LAVA Therapeutics Price Performance

LVTX stock opened at $1.27 on Monday. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.57. The company has a market cap of $33.40 million, a price-to-earnings ratio of -1.23 and a beta of 0.48. The company has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.36.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Friday, March 28th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.40 million. As a group, analysts anticipate that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LVTX. Sanofi purchased a new stake in shares of LAVA Therapeutics during the 4th quarter worth $1,825,000. BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics in the 4th quarter valued at about $40,000. Finally, Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics in the third quarter valued at about $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.